Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Drops to CNY 205.66

Sichuan Biokin Pharmaceutical Co., Ltd. experienced significant volatility on June 1, 2026, with the stock declining by 10.66% and reaching an intraday low of CNY 205.66. This performance starkly contrasts with the China Shanghai Composite, which saw a modest decline of 0.27% on the same day. Over the past week, Sichuan Biokin's stock has dropped 8.52%, and its one-month performance reflects a substantial decrease of 21.85%. Year-to-date, the stock has faced a notable decline of 34.03%, while its one-year performance shows a decrease of 29.23%. In contrast, the China Shanghai Composite has gained 2.24% year-to-date and 21.22% over the past year. The company's financial metrics indicate ongoing challenges, with net sales for the last nine months reported at CNY 2,065.9 million, reflecting a decline of 63.52%. Additionally, the net profit for the same period stands at CNY -500.37 million, marking a significant drop of 112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million, highlighting the company's current financial difficulties.